STAT5A and acute lymphoblastic leukemia: These original findings already pointed to STAT5 as a potential effector of the BCR-ABL tyrosine kinase fusion protein, the transforming agent in Ph+ ALL and chronic myeloid leukemia (CML), and were confirmed a few months later by other groups [15,16].